NuGenerex Immuno-Oncology, Inc.
NuGenerex Immuno-Oncology, Inc.
Your view on NUGX
Overview
What the company does, where it operates, and who runs it.
About NuGenerex Immuno-Oncology, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Joseph Moscato
- Headquarters
- 10102 USA Today Way, Miramar, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Joseph Moscato
- Headquarters
- 10102 USA Today Way, Miramar, FL, US
NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer. The company was formerly known as Antigen Express, Inc. The company was founded in 1993 and is based in Miramar, Florida. NuGenerex Immuno-Oncology, Inc.is a subsidiary of Generex Biotechnology Corporation.
Infographics
Visual summary of the business at a glance.
Media
Videos and interviews covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Comparables
List of peer companies in the same industry.
Institutional Ownership
Which funds and firms own the stock.
Insider Trading
Recent buying and selling by company executives.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
News
Latest headlines and market coverage.